$CKPT
Checkpoint Therapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000110465921101116 Filed on August 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q4 2020 Q2
Revenue $155.0K $30.00K $40.00K
YoY Change 287.5% 0.0% -96.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.114M $2.120M $1.690M
YoY Change 25.09% -1.4% -3.98%
% of Gross Profit
Research & Development $7.198M $8.150M $3.029M
YoY Change 137.64% 21.1% -26.48%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.312M $10.27M $4.716M
YoY Change 97.46% 15.65% -19.77%
Operating Profit -$9.157M -$4.674M
YoY Change 95.91% -3.17%
Interest Expense $13.00K $20.00K $30.00K
YoY Change -56.67% -33.33% -25.0%
% of Operating Profit
Other Income/Expense, Net $13.00K $29.00K
YoY Change -55.17% -17.14%
Pretax Income -$9.144M -$10.23M -$4.650M
YoY Change 96.65% 15.86% -2.92%
Income Tax
% Of Pretax Income
Net Earnings -$9.144M -$10.23M -$4.645M
YoY Change 96.86% 15.86% -3.07%
Net Earnings / Revenue -5899.35% -34100.0% -11612.5%
Basic Earnings Per Share -$0.12
Diluted Earnings Per Share -$0.12 -$159.3K -$89.77K
COMMON SHARES
Basic Shares Outstanding 75.49M
Diluted Shares Outstanding 75.49M

Balance Sheet

Concept 2021 Q2 2020 Q4 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $65.12M $40.77M $21.92M
YoY Change 197.1% 56.33% 65.93%
Cash & Equivalents $65.12M $40.77M $21.92M
Short-Term Investments
Other Short-Term Assets $155.0K $20.00K $42.00K
YoY Change 269.05% -23.08% -95.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $66.12M $42.60M $22.69M
YoY Change 191.48% 57.96% 49.05%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $66.12M $42.60M $22.69M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $66.12M $42.60M $22.69M
YoY Change 191.48% 57.96% 49.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.081M $3.438M $2.321M
YoY Change 118.91% 11.66% -40.03%
Accrued Expenses $289.0K $540.0K $220.0K
YoY Change 31.36% 31.71% 10.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.249M $7.217M $7.711M
YoY Change 19.95% -11.11% -3.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.249M $7.217M $7.711M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $9.249M $7.217M $7.711M
YoY Change 19.95% -11.11% -3.73%
SHAREHOLDERS EQUITY
Retained Earnings -$158.8M -$143.2M -$128.0M
YoY Change 24.06% 19.22%
Common Stock $8.000K $6.000K $5.000K
YoY Change 60.0% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $56.87M $35.38M $14.97M
YoY Change
Total Liabilities & Shareholders Equity $66.12M $42.60M $22.69M
YoY Change 191.48% 57.96% 49.05%

Cashflow Statement

Concept 2021 Q2 2020 Q4 2020 Q2
OPERATING ACTIVITIES
Net Income -$9.144M -$10.23M -$4.645M
YoY Change 96.86% 15.86% -3.07%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.705M -$4.930M -$2.160M
YoY Change 164.12% 4.23% -56.45%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.80M 3.680M 2.610M
YoY Change 313.68% -79.27% -34.91%
NET CHANGE
Cash From Operating Activities -5.705M -4.930M -2.160M
Cash From Investing Activities
Cash From Financing Activities 10.80M 3.680M 2.610M
Net Change In Cash 5.092M -1.250M 450.0K
YoY Change 1031.56% -109.6% -147.37%
FREE CASH FLOW
Cash From Operating Activities -$5.705M -$4.930M -$2.160M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001651407
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Registrant Name
EntityRegistrantName
Checkpoint Therapeutics, Inc.
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62420439
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75741873
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38128
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2568632
dei Entity Address Address Line1
EntityAddressAddressLine1
95 Sawyer Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02453
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652-4500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
CKPT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65124000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40772000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
844000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1804000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
155000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
20000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
66123000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42596000
CY2021Q2 us-gaap Assets
Assets
66123000
CY2020Q4 us-gaap Assets
Assets
42596000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8346000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6367000
CY2021Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
903000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
850000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9249000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7217000
CY2021Q2 us-gaap Liabilities
Liabilities
9249000
CY2020Q4 us-gaap Liabilities
Liabilities
7217000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75741873
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62420439
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q2 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
0
CY2020Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1742449
CY2020Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
4617000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
215706000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
173947000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158841000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143192000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
56874000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66123000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42596000
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
155000
CY2020Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
42000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
223000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1014000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7198000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3029000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11411000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5664000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2114000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1687000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4487000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3365000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
9312000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
4716000
us-gaap Operating Expenses
OperatingExpenses
15898000
us-gaap Operating Expenses
OperatingExpenses
9029000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9157000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4674000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15675000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8015000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
us-gaap Investment Income Interest
InvestmentIncomeInterest
89000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
89000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9144000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4645000
us-gaap Net Income Loss
NetIncomeLoss
-15649000
us-gaap Net Income Loss
NetIncomeLoss
-7926000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75492853
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51802451
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72912456
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51338963
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
54175000
CY2021Q2 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
10824000
CY2021Q2 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
253000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
766000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-9144000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
56874000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
34717000
ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
887000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1540000
us-gaap Net Income Loss
NetIncomeLoss
-15649000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
56874000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
16218000
CY2020Q2 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
2604000
CY2020Q2 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
66000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
731000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4645000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
14974000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18847000
ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
2604000
ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
66000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1370000
ckpt Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
13000
us-gaap Net Income Loss
NetIncomeLoss
-7926000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
14974000
us-gaap Net Income Loss
NetIncomeLoss
-15649000
us-gaap Net Income Loss
NetIncomeLoss
-7926000
us-gaap Share Based Compensation
ShareBasedCompensation
1540000
us-gaap Share Based Compensation
ShareBasedCompensation
1370000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
887000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
66000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-960000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-144000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
135000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
16000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2032000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-339000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10365000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6701000
ckpt Proceeds From Issuance Of Common Stock For At Market Offering
ProceedsFromIssuanceOfCommonStockForAtMarketOffering
35614000
ckpt Proceeds From Issuance Of Common Stock For At Market Offering
ProceedsFromIssuanceOfCommonStockForAtMarketOffering
2666000
ckpt Payment Of Stock Offering Costs
PaymentOfStockOfferingCosts
897000
ckpt Payment Of Stock Offering Costs
PaymentOfStockOfferingCosts
62000
ckpt Issuance Of Common Stock Public Offering
IssuanceOfCommonStockPublicOffering
0
ckpt Issuance Of Common Stock Public Offering
IssuanceOfCommonStockPublicOffering
-69000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34717000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2548000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24352000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4153000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40772000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26077000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65124000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21924000
us-gaap Stock Issued1
StockIssued1
4617000
us-gaap Stock Issued1
StockIssued1
2510000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-158800000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2015Q1 ckpt Equity Method Investment Annual Equity Feepercentage
EquityMethodInvestmentAnnualEquityFeepercentage
0.025
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4560392
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8393903
CY2021Q2 ckpt Common Stock Increase In Shares Authorized
CommonStockIncreaseInSharesAuthorized
40000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 ckpt Shelf Registration Statement Maximum Authorized Securities
ShelfRegistrationStatementMaximumAuthorizedSecurities
100000000
CY2021Q2 ckpt Shelf Registration Statement Remaining Authorized Securities
ShelfRegistrationStatementRemainingAuthorizedSecurities
60300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0104
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0150
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0102
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.0065
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0271
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0127
CY2021Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
766000
CY2020Q2 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
731000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1540000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1370000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5081000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3438000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
289000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
535000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2775000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2009000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
201000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
385000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8346000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6367000

Files In Submission

Name View Source Status
0001104659-21-101116-index-headers.html Edgar Link pending
0001104659-21-101116-index.html Edgar Link pending
0001104659-21-101116.txt Edgar Link pending
0001104659-21-101116-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20210630.xsd Edgar Link pending
tmb-20210630x10q.htm Edgar Link pending
tmb-20210630x10q_htm.xml Edgar Link completed
tmb-20210630xex31d1.htm Edgar Link pending
tmb-20210630xex31d2.htm Edgar Link pending
tmb-20210630xex32d1.htm Edgar Link pending
tmb-20210630xex32d2.htm Edgar Link pending
tmb-20210630_cal.xml Edgar Link unprocessable
tmb-20210630_def.xml Edgar Link unprocessable
tmb-20210630_lab.xml Edgar Link unprocessable
tmb-20210630_pre.xml Edgar Link unprocessable